Thermal Ablation Versus Parathyroidectomy for Secondary Hyperparathyroidism

Launched by CHINESE PLA GENERAL HOSPITAL · Nov 26, 2024

Keywords

ClinConnect Summary

This clinical trial is studying two different treatments for a condition called secondary hyperparathyroidism (SHPT), which often occurs in people with chronic kidney disease. SHPT can cause problems like bone pain, fractures, and heart issues, making life more difficult for patients. The trial aims to compare thermal ablation (a heat-based treatment) and parathyroidectomy (surgery to remove the affected glands) to see which one is more effective at lowering parathyroid hormone levels and improving symptoms like bone pain and muscle weakness. Researchers will also look at any side effects from these treatments.

To participate in the trial, individuals need to be between the ages of 65 and 74 and have persistent high levels of parathyroid hormone despite other treatments not working. They should also be experiencing severe symptoms affecting their quality of life. However, those with certain health issues, like severe bleeding disorders or serious heart problems, cannot join. Participants will have regular check-ups to monitor their hormone levels, calcium levels, and any symptoms they experience. This study is important because it could help improve treatment options for SHPT and enhance the quality of life for many patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • persistent serum iPTH (intact parathyroid hormone) levels \> 800 pg/mL；
• • resistance to calcimimetics, vitamin D, and its analogs, with ineffective conventional internal medicine comprehensive treatment；
• • severe bone pain, osteoporosis, muscle pain, ectopic soft tissue calcification, or other factors affecting quality of life；
• • imaging examinations indicating the presence of at least one enlarged parathyroid gland
• Exclusion Criteria:
• • severe bleeding tendency or coagulation disorders, severe cardiopulmonary abnormalities, and abnormal vital signs such as severe hypertension, arrhythmias, and anemia